508 related articles for article (PubMed ID: 11857350)
1. Impact of BCRP/MXR, MRP1 and MDR1/P-Glycoprotein on thermoresistant variants of atypical and classical multidrug resistant cancer cells.
Stein U; Lage H; Jordan A; Walther W; Bates SE; Litman T; Hohenberger P; Dietel M
Int J Cancer; 2002 Feb; 97(6):751-60. PubMed ID: 11857350
[TBL] [Abstract][Full Text] [Related]
2. Drug concentration-dependent expression of multidrug resistance-associated protein and P-glycoprotein in the doxorubicin-resistant acute myelogenous leukemia sublines.
Choi CH; Kim HS; Rha HS; Jeong JH; Park YH; Min YD; Kee KH; Lim DY
Mol Cells; 1999 Jun; 9(3):314-9. PubMed ID: 10420992
[TBL] [Abstract][Full Text] [Related]
3. Altered MRP is associated with multidrug resistance and reduced drug accumulation in human SW-1573 cells.
Eijdems EW; Zaman GJ; de Haas M; Versantvoort CH; Flens MJ; Scheper RJ; Kamst E; Borst P; Baas F
Br J Cancer; 1995 Aug; 72(2):298-306. PubMed ID: 7640209
[TBL] [Abstract][Full Text] [Related]
4. Overexpression of SCN5A overcomes ABC transporter-mediated multidrug resistance in acute myeloid leukemia through promoting apoptosis.
Xu K; Zhuang XX; Shi XW
Expert Rev Hematol; 2024; 17(1-3):87-94. PubMed ID: 38230679
[TBL] [Abstract][Full Text] [Related]
5. Broad blocking of MDR efflux pumps by acetylshikonin and acetoxyisovalerylshikonin to generate hypersensitive phenotype of malignant carcinoma cells.
Mirzaei SA; Reiisi S; Ghiasi Tabari P; Shekari A; Aliakbari F; Azadfallah E; Elahian F
Sci Rep; 2018 Feb; 8(1):3446. PubMed ID: 29472576
[TBL] [Abstract][Full Text] [Related]
6. Cancer Drug Resistance Reduction via Co-treatment with Oxaliplatin and Nitazoxanide: Targeting the ABC Transporters.
Hemmati-Dinarvand M; Mokhtari H; Alipourfard I; Beyrami Aghbash E; Kheirandish S; Khodadadian A; Seghatoleslam A
Curr Mol Med; 2023; 23(8):834-841. PubMed ID: 35996253
[TBL] [Abstract][Full Text] [Related]
7. Human immunodeficiency virus protease inhibitors serve as substrates for multidrug transporter proteins MDR1 and MRP1 but retain antiviral efficacy in cell lines expressing these transporters.
Srinivas RV; Middlemas D; Flynn P; Fridland A
Antimicrob Agents Chemother; 1998 Dec; 42(12):3157-62. PubMed ID: 9835508
[TBL] [Abstract][Full Text] [Related]
8. Overcoming Multidrug Resistance: Flavonoid and Terpenoid Nitrogen-Containing Derivatives as ABC Transporter Modulators.
M F Gonçalves B; S P Cardoso D; U Ferreira MJ
Molecules; 2020 Jul; 25(15):. PubMed ID: 32722234
[TBL] [Abstract][Full Text] [Related]
9. Chemosensitisation of spontaneous multidrug resistance by a 1,4-dihydropyridine analogue and verapamil in human glioma cell lines overexpressing MRP or MDR1.
Abe T; Koike K; Ohga T; Kubo T; Wada M; Kohno K; Mori T; Hidaka K; Kuwano M
Br J Cancer; 1995 Aug; 72(2):418-23. PubMed ID: 7640227
[TBL] [Abstract][Full Text] [Related]
10. Flow cytometric functional analysis of multidrug resistance by Fluo-3: a comparison with rhodamine-123.
Koizumi S; Konishi M; Ichihara T; Wada H; Matsukawa H; Goi K; Mizutani S
Eur J Cancer; 1995 Sep; 31A(10):1682-8. PubMed ID: 7488425
[TBL] [Abstract][Full Text] [Related]
11. The Effect of Nanosystems on ATP-Binding Cassette Transporters: Understanding the Influence of Nanosystems on Multidrug Resistance Protein-1 and P-glycoprotein.
Mello FVC; de Moraes GN; Maia RC; Kyeremateng J; Iram SH; Santos-Oliveira R
Int J Mol Sci; 2020 Apr; 21(7):. PubMed ID: 32290047
[TBL] [Abstract][Full Text] [Related]
12. Isolation and characterization of daunorubicin-resistant AML-2 sublines.
Choi CH; Ling V
Mol Cells; 1997 Apr; 7(2):170-7. PubMed ID: 9163728
[TBL] [Abstract][Full Text] [Related]
13. The PI3K subunits, P110α and P110β are potential targets for overcoming P-gp and BCRP-mediated MDR in cancer.
Zhang L; Li Y; Wang Q; Chen Z; Li X; Wu Z; Hu C; Liao D; Zhang W; Chen ZS
Mol Cancer; 2020 Jan; 19(1):10. PubMed ID: 31952518
[TBL] [Abstract][Full Text] [Related]
14. NAT10-mediated mRNA N4-acetylcytidine modification of MDR1 and BCRP promotes breast cancer progression.
Zhao CC; Sun X; Chen J; Geng BD
Thorac Cancer; 2024 Apr; 15(10):820-829. PubMed ID: 38409918
[TBL] [Abstract][Full Text] [Related]
15. Intracellular localization, vesicular accumulation and kinetics of daunorubicin in sensitive and multidrug-resistant gastric carcinoma EPG85-257 cells.
Seidel A; Hasmann M; Löser R; Bunge A; Schaefer B; Herzig I; Steidtmann K; Dietel M
Virchows Arch; 1995; 426(3):249-56. PubMed ID: 7773504
[TBL] [Abstract][Full Text] [Related]
16. Combination of 7-
Chen Y; Li X; Shi L; Ma P; Wang W; Wu N; Gan Y; Han X; Huang S; Kang X; Liu S; Zhen Y
Aging (Albany NY); 2022 Sep; 14(17):7156-7169. PubMed ID: 36107024
[TBL] [Abstract][Full Text] [Related]
17. Protein kinase Cα protects against multidrug resistance in human colon cancer cells.
Lee SK; Shehzad A; Jung JC; Sonn JK; Lee JT; Park JW; Lee YS
Mol Cells; 2012 Jul; 34(1):61-9. PubMed ID: 22639047
[TBL] [Abstract][Full Text] [Related]
18. Drug resistance mechanisms and MRP expression in response to epirubicin treatment in a human leukaemia cell line.
Davey RA; Longhurst TJ; Davey MW; Belov L; Harvie RM; Hancox D; Wheeler H
Leuk Res; 1995 Apr; 19(4):275-82. PubMed ID: 7752673
[TBL] [Abstract][Full Text] [Related]
19. Cyclosporin A, verapamil and S9788 reverse doxorubicin resistance in a human medullary thyroid carcinoma cell line.
Massart C; Gibassier J; Raoul M; Pourquier P; Leclech G; Robert J; Lucas C
Anticancer Drugs; 1995 Feb; 6(1):135-46. PubMed ID: 7756676
[TBL] [Abstract][Full Text] [Related]
20. Doxorubicin treatment modulates chemoresistance and affects the cell cycle in two canine mammary tumour cell lines.
Levi M; Salaroli R; Parenti F; De Maria R; Zannoni A; Bernardini C; Gola C; Brocco A; Marangio A; Benazzi C; Muscatello LV; Brunetti B; Forni M; Sarli G
BMC Vet Res; 2021 Jan; 17(1):30. PubMed ID: 33461558
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
